| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Carl C. Icahn Institute for Gene Therapy and Molecular Medicine and
Department of Surgery, Mount Sinai School of Medicine, New York, NY 10029
The interactions between NK cells and dendritic cells (DCs) have been previously demonstrated in vitro. In this report, the in vivo cross-regulation between NK cells and DCs was studied in tumor-bearing mice treated with adenoviral vector expressing IL-12 and agonistic anti-4-1BB Abs. NK cells are essential for both tumor rejection and CTL development in the combination therapy (IL-12 plus anti-4-1BB). The numbers and functional activities of both NK cells and DCs in tumor-infiltrating leukocytes were synergistically increased in the IL-12 plus anti-4-1BB-treated mice compared with treatment with either reagent alone. NK depletion in vivo resulted in a significant decrease in the number of DCs in tumor-infiltrating leukocytes, strongly suggesting that NK cells are involved in the activation and expansion of DCs. The mechanism by which IL-12-activated NK cells regulate DC functions is, in part, mediated through the secretion of IFN-
that leads to the up-regulation of 4-1BB by DCs. Furthermore, 4-1BB activation in conjunction with IL-12 gene delivery increased tumor infiltration of green fluorescence protein-labeled DCs and enhanced their MHC class II expression. The activation of DCs by NK cells and the subsequent development of antitumoral CTL responses facilitated by 4-1BB-activated DCs may account for the synergistic effects observed in the combination therapy in comparison to adenoviral vector expressing IL-12 or anti-4-1BB treatment alone.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  W. Lin, C. J. Voskens, X. Zhang, D. G. Schindler, A. Wood, E. Burch, Y. Wei, L. Chen, G. Tian, K. Tamada, et al. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies Blood, August 1, 2008; 112(3): 699 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-R. Chang, K.-J. Wang, Y.-F. Lu, L.-J. Yang, W.-J. Chen, Y.-H. Lin, H.-H. Chang, and S.-L. Wang Characterization of Early Gamma Interferon (IFN-{gamma}) Expression during Murine Listeriosis: Identification of NK1.1+ CD11c+ Cells as the Primary IFN-{gamma}-Expressing Cells Infect. Immun., March 1, 2007; 75(3): 1167 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Houtenbos, T. M. Westers, A. Dijkhuis, T. D. de Gruijl, G. J. Ossenkoppele, and A. A. van de Loosdrecht Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting Clin. Cancer Res., January 1, 2007; 13(1): 307 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kofidis, J. L. deBruin, M. Tanaka, M. Zwierzchoniewska, I. Weissman, E. Fedoseyeva, A. Haverich, and R. C. Robbins They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 461 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Warren, A. L. Jones, C. Freeman, J. Bettadapura, and C. R. Parish Evidence That the Cellular Ligand for the Human NK Cell Activation Receptor NKp30 Is Not a Heparan Sulfate Glycosaminoglycan J. Immunol., July 1, 2005; 175(1): 207 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Imai, S. Iwamoto, and D. Campana Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells Blood, July 1, 2005; 106(1): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
